We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Global Blood to Seek Approval of Oxbryta in Europe for SCD
Read MoreHide Full Article
Global Blood Therapeutics, Inc. announced that it plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Oxbryta (voxelotor) tablets. The company is seeking approval of the drug to treat hemolytic anemia in sickle cell disease (SCD) patients aged 12 years and older. It plans to submit the MAA by mid-2021.
In November 2019, the FDA approved Oxbryta as an oral, once-daily treatment for SCD in patients aged 12 years or above. Following this, the drug became the first and only therapy that directly inhibits sickle hemoglobin polymerization, a major cause for SCD. SCD is a chronic, inherited blood disorder that affects hemoglobin levels.
The planned MAA will include data from the phase III HOPE study and the phase II HOPE-KIDS 1 Study. Global Blood also intends to initiate an Early Access Program in Europe for patients and physicians who may need access to Oxbryta prior to potential marketing authorization.
Anemia and hemolysis are known to cause morbidity and mortality in SCD. Currently, there are no approved therapies in Europe to treat hemolytic anemia in SCD. Thus, the company intends to introduce a treatment for the disease.
Shares of Global Blood have declined 18.8% so far this year against the industry’s growth of 11.9%.
In June 2020, the companyannounced plans to expand the label of Oxbryta in the United States, which will include a new, age-appropriate formulation, for the treatment of SCD in children 4 to 11 years, under the FDA’s accelerated approval pathway. The NDA will include clinical data from the ongoing phase IIa HOPE-KIDS 1 study.
The company has another pipeline candidate, inclacumab, which is a novel, fully-human monoclonal antibody against P-selectin. The drug is being developed as a treatment for vaso-occlusive crises (“VOC”) in patients with SCD. The company is developing inclacumab with drug giant Roche Holding AG (RHHBY - Free Report) .
Last year, the FDA also approved Novartis’ (NVS - Free Report) Adakveo (crizanlizumab) to lower the frequency of VOCs or pain crises in SCD patients aged 16 years or above. bluebird bio E) is also developing LentiGlobin for the treatment of VOC in patients with SCD.
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Global Blood to Seek Approval of Oxbryta in Europe for SCD
Global Blood Therapeutics, Inc. announced that it plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Oxbryta (voxelotor) tablets. The company is seeking approval of the drug to treat hemolytic anemia in sickle cell disease (SCD) patients aged 12 years and older. It plans to submit the MAA by mid-2021.
In November 2019, the FDA approved Oxbryta as an oral, once-daily treatment for SCD in patients aged 12 years or above. Following this, the drug became the first and only therapy that directly inhibits sickle hemoglobin polymerization, a major cause for SCD. SCD is a chronic, inherited blood disorder that affects hemoglobin levels.
The planned MAA will include data from the phase III HOPE study and the phase II HOPE-KIDS 1 Study. Global Blood also intends to initiate an Early Access Program in Europe for patients and physicians who may need access to Oxbryta prior to potential marketing authorization.
Anemia and hemolysis are known to cause morbidity and mortality in SCD. Currently, there are no approved therapies in Europe to treat hemolytic anemia in SCD. Thus, the company intends to introduce a treatment for the disease.
Shares of Global Blood have declined 18.8% so far this year against the industry’s growth of 11.9%.
In June 2020, the companyannounced plans to expand the label of Oxbryta in the United States, which will include a new, age-appropriate formulation, for the treatment of SCD in children 4 to 11 years, under the FDA’s accelerated approval pathway. The NDA will include clinical data from the ongoing phase IIa HOPE-KIDS 1 study.
The company has another pipeline candidate, inclacumab, which is a novel, fully-human monoclonal antibody against P-selectin. The drug is being developed as a treatment for vaso-occlusive crises (“VOC”) in patients with SCD. The company is developing inclacumab with drug giant Roche Holding AG (RHHBY - Free Report) .
Last year, the FDA also approved Novartis’ (NVS - Free Report) Adakveo (crizanlizumab) to lower the frequency of VOCs or pain crises in SCD patients aged 16 years or above. bluebird bio E) is also developing LentiGlobin for the treatment of VOC in patients with SCD.
Global Blood Therapeutics, Inc. Price
Global Blood Therapeutics, Inc. price | Global Blood Therapeutics, Inc. Quote
Zacks Rank
Global Blood currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>